New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al
Transl Oncol. 2024 Jun:44:101820.
doi: 10.1016/j.tranon.2023.101820.
Epub 2023 Nov 15.
1 Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria; Department of Internal Medicine I, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria. Electronic address: tobias.kiesslich@pmu.ac.at.
2 Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria; Department of Internal Medicine I, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria. Electronic address: christian.mayr@pmu.ac.at.
3 Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria. Electronic address: dino.bekric@pmu.ac.at.
4 Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), 5020 Salzburg, Austria; Cancer Cluster Salzburg, 5020 Salzburg, Austria. Electronic address: d.neureiter@salk.at.